{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:18:21Z","timestamp":1787977101343,"version":"build-2784847793"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The front-line (1L) treatment landscape for newly diagnosed multiple myeloma (NDMM) is rapidly evolving with guidelines endorsing triplet and quadruplet regimens as new standard-of-care. Despite this, real-world evidence on current treatment patterns for NDMM remain limited, especially in community settings, where most care is delivered. This study describes 1L treatment patterns for NDMM using recent data from a large US community oncology network.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, observational study analyzed structured and unstructured medical records of patients treated at Texas Oncology. Patients with NDMM (aged \u226518 years) who initiated 1L between January 2015 and December 2022 were included. Patient characteristics, 1L treatment patterns, and temporal trends were described.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>3592 patients with NDMM who initiated 1L treatment were included. From 2015 to 2022, there was a nominal increase in the use of triplet regimens (59.9% to 87.6%). Quadruplet regimen use emerged in 2020 and rose from &amp;lt;1% to 9.4% in 2022. Daratumumab-based regimens numerically increased from 2% in 2019 to 29% in 2022. Daratumumab was integral to all quadruplet therapy regimens used by Texas Oncology centers and was predominantly utilized in the DVRd regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this analysis, adoption of novel 1L regimens for NDMM, particularly daratumumab-based triplet and quadruplet regimens, was observed in recent years. However, the use of quadruplet regimens was still low in 2022, highlighting an opportunity for increased quadruplet uptake in the real-world. Future analysis will be essential to quantify the evolving uptake of quadruplet regimens in 1L and their impact on patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1736892","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:44:16Z","timestamp":1776858256000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Front-line treatment approaches in multiple myeloma: real-world data from a community-based oncology network"],"prefix":"10.3389","volume":"16","author":[{"given":"R. Steve","family":"Paulson","sequence":"first","affiliation":[{"name":"Texas Oncology Professional Association (PA)","place":["Dallas, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Gautam","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Medhekar","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraje","family":"Mahmud","sequence":"additional","affiliation":[{"name":"Precision Health Informatics, LLC","place":["Dallas, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayda","family":"Mirsalehi","sequence":"additional","affiliation":[{"name":"Precision Health Informatics, LLC","place":["Dallas, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ensley","sequence":"additional","affiliation":[{"name":"Precision Health Informatics, LLC","place":["Dallas, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shelley","sequence":"additional","affiliation":[{"name":"Precision Health Informatics, LLC","place":["Dallas, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Brisbin","sequence":"additional","affiliation":[{"name":"Precision Health Informatics, LLC","place":["Dallas, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Lisi","sequence":"additional","affiliation":[{"name":"Texas Oncology Professional Association (PA)","place":["Dallas, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipin","family":"Khare","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuchita","family":"Kaila","sequence":"additional","affiliation":[{"name":"Johnson & Johnson","place":["Horsham, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Yair","family":"Levy","sequence":"additional","affiliation":[{"name":"Texas Oncology Professional Association (PA)","place":["Dallas, TX, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1800451","article-title":"Recent real-world treatment patterns and outcomes in US patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Bruno","year":"2020","journal-title":"Expert Rev Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2024.2432815","article-title":"Optimizing treatment sequencing in multiple myeloma: a novel model to predict survival outcomes","volume":"29","author":"Petrucci","year":"2024","journal-title":"Hematology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19269","article-title":"Emerging drugs and combinations to treat multiple myeloma","volume":"8","author":"Larocca","year":"2017","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.26","article-title":"Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial","volume":"23","author":"Reeder","year":"2009","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"key":"B11","unstructured":"FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for multiple myeloma\n          \n          \n          \n          2024"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02505-2","article-title":"Daratumumab\/lenalidomide\/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes","volume":"39","author":"Facon","year":"2025","journal-title":"Leukemia"},{"key":"B14","unstructured":"FDA approves daratumumab for multiple myeloma ineligible for autologous stem cell transplant\n          \n          \n          \n          2019"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","author":"Facon","year":"2024","journal-title":"N Engl J Med"},{"key":"B16","unstructured":"FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma\n          \n          \n          391\n          2024"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7","article-title":"Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial","volume":"31","author":"Usmani","year":"2025","journal-title":"Nat Med"},{"key":"B18","unstructured":"FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma\n          \n          \n          \n          2026"},{"key":"B19","volume-title":"Multiple myeloma version 4.2026","year":"2025"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2504318","article-title":"Multiple myeloma care, treatment patterns, and treatment durations in academic and community care settings","volume":"21","author":"Boytsov","year":"2025","journal-title":"Future Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"7873","DOI":"10.1182\/blood-2024-211858","article-title":"Evolving patterns of MRD testing and first-line treatment in multiple myeloma: insights from academic and community practices in the US","volume":"144","author":"Franceschetti","year":"2024","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1182\/blood-2024-204730","article-title":"Frontline treatment patterns in patients with newly diagnosed multiple myeloma - real-world evidence from a large community-based oncology practice network in the US","volume":"144","author":"Gordan","year":"2024","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02807-y","article-title":"Adjusted indirect treatment comparison of progression-free survival with D-Rd and VRd based on MAIA and SWOG S0777 individual patient-level data","volume":"41","author":"Durie","year":"2024","journal-title":"Adv Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clml.2023.09.003","article-title":"Progression-free survival of daratumumab versus bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study","volume":"24","author":"Gordan","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25963","article-title":"Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: Efficacy in transplant-ineligible untreated myeloma","volume":"95","author":"Durie","year":"2020","journal-title":"Am J Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.3323","article-title":"Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States","volume":"31","author":"Warren","year":"2013","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.46989\/001c.133682","article-title":"Consensus guidelines and recommendations for the CD38 monoclonal antibody-based quadruplet therapy and management in clinical practice for newly diagnosed multiple myeloma: from the Pan-Pacific Multiple Myeloma Working Group","volume":"7","author":"Chen","year":"2025","journal-title":"Clin Hematol Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2342228","article-title":"Clinical consensus on treatments for transplant-ineligible newly diagnosed multiple myeloma: double-blinded Delphi panel","volume":"20","author":"Fonseca","year":"2024","journal-title":"Future Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41408-025-01253-5","article-title":"Daratumumab-based quadruplet versus triplet induction regimens in transplant-eligible newly diagnosed multiple myeloma: a systematic review and meta-analysis","volume":"15","author":"Souto Filho","year":"2025","journal-title":"Blood Cancer J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0020","article-title":"Drivers of physician decision-making and patient perspectives across lines of therapy in multiple myeloma in the USA","volume":"19","author":"Ribbands","year":"2023","journal-title":"Future Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1736892\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:44:19Z","timestamp":1776858259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1736892\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":30,"alternative-id":["10.3389\/fonc.2026.1736892"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1736892","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1736892"}}